ProKidney’s rilparencel, a cell therapy for chronic kidney disease (CKD), presented mixed findings in a phase 2 trial. One cohort receiving two injections demonstrated a significant 78% slowing in annual kidney function decline, while a second cohort with optional second dosing showed a non-significant 50% improvement. The firm plans a phase 3 study using the robust dosing schedule and aims for accelerated approval based on eGFR slope as the surrogate endpoint. No serious adverse events were connected to the treatment. The data led to a substantial stock price rally for ProKidney.